The purpose of this study was to assess the incidence rate of the major adverse cardiovascular events (MACE) and safety of fenofibrate (Lipilfen capsule) add-on statin therapy in patients who have history of acute myocardial infarction and are diagnosed with metabolic syndrome.

Inclusion Criteria:

• patients >20 years of age.
• history of acute myocardial infarction
• metabolic syndrome diagnosis

Exclusion Criteria:

• current liver disease or AST or ALT greater than 3 times the upper limit of reference range
• pre-existing gallbladder disease
• moderate to severe renal disorder (serum creatinine >2.5mg/dL)
• pancreatitis diagnosis

Subjects aged more than 20 with history of acute myocardial infarction and diagnosed with metabolic syndrome